Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Latest Information Update: 22 Oct 2024
Price :
$35 *
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 18 Oct 2024 Planned End Date changed from 30 Sep 2025 to 31 Dec 2029.
- 18 Oct 2024 Planned primary completion date changed from 30 Sep 2024 to 31 Dec 2028.
- 03 Jul 2024 Planned number of patients changed from 120 to 130.